Home
Clinical Resources Search
PQI: Daratumumab (Darzalex®) for Multiple Myeloma

Daratumumab (Darzalex®) for Multiple Myeloma

Last Updated: May 22, 2024

By: Lauren Trisler, PharmD, BCOP

About this PQI

Daratumumab is an anti-CD38 monoclonal antibody (mAb) FDA approved for use in a range of multiple myeloma patients including first line, transplant-ineligible, and refractory.1 This PQI will provide guidance for optimal administration and management of both daratumumab infusions and subcutaneous formulation.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI